Interventional Combined Microwave Ablation for Primary Neuroendocrine Carcinoma of the Liver Failing Systemic Chemotherapy: A Case Report

Yang Fang,Xiuying Jin,Huiying Cui,Zhezhu Han,Qiang Xu,Songnan Zhang

DOI: https://doi.org/10.2147/jhc.s484272

2024-11-29

Journal of Hepatocellular Carcinoma

Abstract:Yang Fang, Xiuying Jin, Huiying Cui, Zhezhu Han, Qiang Xu, Songnan Zhang Department of Oncology, Yanbian University Hospital, Yanji, People's Republic of China Correspondence: Songnan Zhang, Email Background: Primary hepatic Neuroendocrine carcinoma (PHNEC) is exceptionally rare, and when it cannot be surgically removed locally, systemic combination therapy is the preferred treatment. However, current treatments have shown limited effectiveness, and more effective approach remains a matter of debate. Case Presentation: We present a case involving a female patient diagnosed with non-surgically suitable PHNEC, confirmed through pathology. Following four cycles of standard first-line systemic chemotherapy, this intervention was prompted by imaging indicating suboptimal local lesion control, the patient underwent localized interventional and microwave ablation therapy. Subsequently, an evaluation based on mRECIST criteria revealed complete remission post-procedure. The disease sustained this remission status throughout the 14-month follow-up, with the administration of 14 cycles of immunocheckpoint inhibitor maintenance therapy, showing no signs of local recurrence or distant metastasis and devoid of any associated complications. Conclusion: This case introduces a novel therapeutic avenue for individuals who are ineligible for surgery and have not responded to systemic chemotherapy. The diagnosis and management of PHNEC are deliberated within the framework of this particular case. Keywords: primary hepatic neuroendocrine carcinoma, large cell, neuroendocrine carcinoma, interventional, liver Primary hepatic neuroendocrine carcinoma (PHNEC) is an exceptionally rare and diverse tumor arising from neuroendocrine cells, constituting approximately 0.3% of all neuroendocrine tumors. 1 Owing to the lack of distinctive specificity in symptoms, signs, and imaging, it is easily confused with other liver tumors, 2 diagnosis primarily depends on histopathologic examination through percutaneous puncture biopsy. Conventional imaging, coupled with growth inhibitory hormone receptor imaging (eg, PET-CT), is employed to rule out other primary lesions. The prognosis for PHNEC is notably grim, with a reported 1-year survival rate of 23.5% and a 5-year survival rate of 5.8%. The median overall survival is 16.5 months. 3 Neuroendocrine carcinoma is a highly aggressive disease; early radical surgery prolongs patient survival; most patients are found to have metastases, and the standard regimen is systemic chemotherapy, however, the therapeutic effect was suboptimal; interventional and ablative therapies are seldom used for this disease. 4 We present a case of PHNEC wherein the patient underwent treatment involving Transarterial Chemoembolization (TACE) combined with microwave ablation for intrahepatic lesions that exhibited persistent size and heterogeneous enhancement on imaging after four cycles of systemic chemotherapy. Postoperative follow-up assessments, utilizing modified solid tumor evaluation criteria, indicated the patient's complete remission status. The patient continued with 14 cycles of immune checkpoint inhibitors, with no evidence of local recurrence or distant metastasis observed over the 14-month follow-up period. The patient is a 64-year-old female with a medical history notable for hypertension and diabetes mellitus. She denied any history of hepatitis or alcohol consumption. In February 2022, she sought medical attention at a local hospital due to poor appetite and intermittent abdominal pain persisting for over 2 months. Imaging examinations suggested a high likelihood of primary hepatocellular carcinoma, leading to her admission to our hospital for further assessment. Upon examination, there were no evident positive signs. Liver function tests and tumor markers, including alpha-fetoprotein and carcinoembryonic antigen, showed no abnormalities. Neuron-specific enolase (NSE) level was measured at 73.8 U/mL. Enhanced CT of the entire abdomen revealed round masses in the right lobe of the liver near the hilar region and the right posterior lobe, exhibiting a maximum diameter of 8.5 cm. Post-enhancement, the masses displayed inhomogeneous enhancement, distinct contouring in the portal and delayed phases, and partial indistinctness from the portal vein (Figure 1). Chest CT and cranial nuclear magnetic scanning ruled out other primary lesions. On February 19, 2022, percutaneous hepatic puncture biopsy, guided by ultrasound, was conducted. Pathology results indicated neuroendocrine carcinoma of the liver, specifically the large-cell type. Immunohistochemistry revealed tumor cells with CK7 (-), CK20 (-), weak CK8/18 expression, Heppar-1 (-), GPC-3 (-), Syn (+), CgA (+), NSE (+), and Ki-67 (70%+) (Figure 2). Histolog -Abstract Truncated-

oncology